1. Psychotropic Agents
These are drugs that cure mental disorders.
Mental disorders includes abnormal changes in
how a person feels, acts, thinks or perceives
which degrades ability to function in ordinary
life or socialize with others
– Anxiolytic
– Antidepressents
– Antiphycotics
3. Anxiety
• Anxiety is a normal fear response to stress or
threats. It helps us to prepare for a “fight or
flight” action
• Too much or unnecessary anxiety can cause
stress related disorders ranging from
cognitive block to pain and heart palpitations
(abnormal heart beat)
4. Types of Anxiety
• General Anxiety
• Obsessive Compulsive Disorder
• Panic Disorder
• Post Traumatic Stress Disorder
• Specific Phobias
• Social Anxiety
5. Is anxiety really a disease? Yes
Clinical effects of General Anxiety
• Constant worrying or obsession about small or large
concerns
• Restlessness and feeling on edge
• Fatigue
• Difficulty concentrating or your mind "going blank"
• Irritability
• Muscle tension or muscle aches
• Trembling, feeling twitchy or being easily startled
• Trouble sleeping
• Sweating, nausea or diarrhea
• Shortness of breath or rapid heartbeat
6. Drugs used to treat Anxiety are
1) Benzodiazepines:
– Chordiazepoxide, Clonazepam,
– Alprazolam, Diazepam*, Lorazepam
2) Azapirones - Buspirone
7. Chlordiazepoxide
• It is a long acting benzodiazepam
• It has amnestic, anticonvulsant, anxiolytic, hypnotic
and skeletal muscle relaxant properties
• It has an intermediate onset of action (15-30 mins),
with a peak blood level occurring two to four hours
after oral administration. It has active metabolite
• Used for the short-term (2–4 weeks) treatment of
anxiety
• It’s long term use can cause depression, tolerance and
dependence with withdrawal effects similar to alcohol
• MOA- Anxiolytic effect is due to CNS depression caused
by stimulation of GABAA receptors
8. Clonazepam
• It is a intermediate acting benzodiazepam
• It has amnestic, anticonvulsant, anxiolytic, hypnotic and
skeletal muscle relaxant properties
• It has an intermediate onset of action (15-30 mins), with a
peak blood level occurring one to four hours after oral
administration
• Used for the short-term (2-4) treatment of panic disorder
(recurring panic attacks- palpitations, shaking and chest
pain)
• It’s long term use can cause depression, tolerance and
dependence with withdrawal effects similar to alcohol
• MOA- Anxiolytic effect is due to CNS depression caused by
stimulation of GABAA receptors
9. Azapirones: Buspirone
• Azapirones are a class of drugs having both anxiolytics and
antipsychotics activity
• Anxiolytic action due to agonism at serotonin (5-HT]) type
1A receptor
• antipsychotics activity is due to antagonism at D2 receptor
• It has delayed onset of action but
• As potent as diazepam with no tolerance and addictiveness
and no sedative effects, no cognitive or motor impairment
• They are very especially safe and effective in elderly
patients
• Used limited for mild to moderate anxiety and not useful in
severe cases like panic attack
13. • SAR is developed by analyzing activity of a series of
drugs with a small alteration made around a common
structure
• These alteration must be planned carefully so that
effective comparisons can be made
• We can judge in above compounds that
– Substituting Nitrogen decreses activity (1st and 2nd)
– Removing hydroxyl group improves activity (1st and 4th)
– Having an extra aromatic nitrogen ring is good and
compensates lack of Chlorine in lower ring(6th and 7th)
– We know that for diazepams, having electronegative
groups at specific positions is essential for activity and it
reflected in these 8 marketed compounds but to include it
as a valid SAR we need to compare it’s activity with those
structures that lack those electronegative groups
• But these small alteration have big changes in ADME
14.
15. Assignment
• Refer the given research article and point out
SAR of drugs called HDAC inhibitors
• European Journal of Medicinal Chemistry 44
(2009) 1067e1085
• Key skill gained:
• Knowledge on various structural diversity that
can be implemented for drug design